Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mulberry Twig Alkaloids for Diabetic Nephropathy (Phase 4 RCT)
ChiCTR2500106214Phase 4Not yet recruiting
- Sponsor
- The Second Hospital of Jilin University
- Start
- Jul 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sangzhi total alkaloids in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The Second Hospital of Jilin University. Primary endpoint: Urinary Albumin-to-Creatinine Ratio (UACR) at 16 week. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
sangzhi total alkaloids
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500106214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106214.